Clinical Trials
50 trialsNCT05730712 2026-05-15
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT03365882 2026-02-10
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
SWOG Cancer Research Network
Phase 2 Completed
NCT01796197 2026-02-05
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT02205047 2025-07-31
INNOVATION
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT02252887 2025-07-25
Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01817452 2025-02-26
ADAPT
West German Study Group
Phase 2 Completed
NCT04551521 2025-01-08
CRAFT: The NCT-PMO-1602 Phase II Trial
German Cancer Research Center
Phase 2 Completed
NCT04632992 2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2 Completed
NCT03644186 2024-12-13
TOUCH
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT02339532 2024-11-08
NeoTOP
UNICANCER
Phase 2 Completed
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT02291289 2024-05-06
MODUL
Hoffmann-La Roche
Phase 2 Completed
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT03674112 2024-01-02
PHranceSCa
Hoffmann-La Roche
Phase 2 Completed
NCT03742986 2023-12-19
Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
NYU Langone Health
Phase 2 Completed
NCT03845270 2023-12-19
R2D2
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT03988036 2023-05-15
Keyriched-1
West German Study Group
Phase 2 Completed
NCT01597414 2022-11-17
Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT02789657 2022-05-19
Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
Brown University
Phase 2 Completed
NCT01904903 2022-05-10
SAFE-HEaRt
Medstar Health Research Institute
Phase 2 Completed
NCT02536339 2021-12-07
A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
Genentech, Inc.
Phase 2 Completed
NCT02073487 2021-09-22
TEAL
The Methodist Hospital Research Institute
Phase 2 Completed
NCT02132949 2021-09-17
BERENICE
Hoffmann-La Roche
Phase 2 Completed
NCT01847001 2021-09-10
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Columbia University
Phase 2 Completed
NCT02909751 2021-05-20
NeoToc
Vejle Hospital
Phase 2 Completed
NCT01835236 2021-03-30
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
Swiss Cancer Institute
Phase 2 Completed
NCT02682693 2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2 Completed
NCT01491737 2020-10-28
PERTAIN
Hoffmann-La Roche
Phase 2 Completed
NCT01276041 2020-08-03
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02530424 2020-07-15
NA-PHER2
Fondazione Michelangelo
Phase 2 Completed
NCT01855828 2020-03-31
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
Yale University
Phase 2 Completed
NCT01959490 2019-03-05
Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02411344 2018-09-18
PER-ELISA
Istituto Oncologico Veneto IRCCS
Phase 2 Completed
NCT01461057 2018-08-09
JOSHUA
Hoffmann-La Roche
Phase 2 Completed
NCT00545688 2017-08-15
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT00058552 2017-03-08
A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer
Genentech, Inc.
Phase 2 Completed
NCT00976989 2017-02-06
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT01565083 2016-11-22
VELVET
Hoffmann-La Roche
Phase 2 Completed
NCT01674062 2016-08-22
A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT01121939 2016-02-05
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02491892 2015-08-25
A Study of Pertuzumab in Participants With Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00063154 2015-07-07
Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy
Genentech, Inc.
Phase 2 Completed
NCT00058539 2015-06-23
Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
Genentech, Inc.
Phase 2 Completed
NCT00096941 2015-06-11
A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT00096993 2015-06-10
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Genentech, Inc.
Phase 2 Completed
NCT02004093 2014-12-04
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00943670 2013-05-27
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
Genentech, Inc.
Phase 2 Completed
NCT00855894 2013-05-21
PENGUIN
Genentech, Inc.
Phase 2 Completed
NCT00301899 2012-03-08
Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab
National Institutes of Health Clinical Center (CC)
Phase 2 Completed